Verseon begins dosing in phase 1 trial of VE-1902 oral anticoagulant

This article was originally published here

The early-stage trial will study safety, pharmacokinetics, and pharmacodynamics of VE-1902 in 100-120 participants. The blood thinner is the first PRrecision Oral AntiCoagulant (PROAC) of the US-based pharma

The post Verseon begins dosing in phase 1 trial of VE-1902 oral anticoagulant appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply